0000000000135601

AUTHOR

Gabriella La Rocca

showing 4 related works from this author

One-year renal and cardiac effects of bisoprolol versus losartan in recently diagnosed hypertensive patients: a randomized, double-blind study.

2009

BACKGROUND AND OBJECTIVES: Hypertension is a significant cause of chronic renal injury and its effective treatment is capable of reducing the rate of renal failure. beta-Adrenoceptor antagonists (beta-blockers) have been reported to induce a deterioration in renal function, while several data have indicated a renoprotective effect of treatment with the angiotensin II type 1 receptor antagonist losartan. Previous studies of the interaction between the selective beta(1)-blocker bisoprolol and kidney function were performed only for short- and medium-term periods. The aim of this study was to compare the antihypertensive efficacy and renal and cardiac haemodynamic effects of bisoprolol with th…

AdultMalemedicine.medical_specialtyTime Factorsmedicine.drug_classRenal functionHemodynamicsEssential hypertensionKidneyKidney Function TestsLosartanlaw.inventionRandomized controlled trialDouble-Blind MethodlawInternal medicinemedicineBisoprololHumansPharmacology (medical)Antihypertensive Agentshypertension losartanbisiprololbusiness.industryHeartGeneral MedicineMiddle AgedReceptor antagonistmedicine.diseaseAngiotensin IILosartanBisoprololHeart Function TestsHypertensionCardiologyFemalebusinessmedicine.drug
researchProduct

Is delayed facilitated percutaneous coronary intervention better than immediate in reperfused myocardial infarction? Six months follow up findings

2006

Background: There are several new strategies proposed to improve the outcome of patients with ST-elevation myocardial infarction (STEMI). One approach is the resurgent use of facilitated percutaneous coronary interventions (PCI). Until recently, deciding whether immediate PCI after combined treatment (facilitated PCI) is more appropriate than delayed PCI (short time) has not been investigated. The aim of this study, therefore, was to investigate the outcomes in patients initially successfully treated pharmacologically and immediate PCI < 2 hr, and in patients initially successfully treated with pharmacological therapy and with delayed PCI (12–72 h). Methods: 451 reperfused STEMI patients, a…

Malemedicine.medical_specialtyTiclopidineTime Factorsmedicine.medical_treatmentMyocardial InfarctionFacilitated Percutaneous Coronary InterventionPlatelet Glycoprotein GPIIb-IIIa ComplexGIIb/IIIa inhibitorDelayed Percutaneous Coronary InterventionsInternal medicineAngioplastymedicineAbciximabAcute myocardial InfarctionHumanscardiovascular diseasesMyocardial infarctionAngioplasty Balloon CoronaryAgedbusiness.industryAnticoagulantsPercutaneous coronary interventionHematologyTirofibanMiddle AgedClopidogrelmedicine.diseaseCombined Modality TherapyClopidogrelsurgical procedures operativeTissue Plasminogen ActivatorConventional PCICardiologyFemaleCardiology and Cardiovascular MedicinebusinesstherapeuticsCombined therapyPlatelet Aggregation InhibitorsTIMIFollow-Up Studiesmedicine.drugJournal of Thrombosis and Thrombolysis
researchProduct

Medium-term effects of bisoprolol administration on renal hemodynamics and function in mild to moderate essential hypertension

2007

Arterial hypertension is a significant cause of end-stage renal failure; effective treatment of hypertensive patients reduces the rate of progression of this disorder. ss-Blockers, particularly nonselective agents, are associated with deterioration of renal function in patients with chronic renal failure. Previous studies on the interaction of the beta1-selective adrenergic antagonist bisoprolol with kidney function have been performed only acutely and over the short term. This study was designed to evaluate the antihypertensive efficacy and effects on renal hemodynamics and function of bisoprolol during medium-term (6 mo) treatment of patients with mild to moderate essential hypertension. …

renal hemodynamicsAdultMalemedicine.medical_specialtySettore MED/09 - Medicina InternaAdrenergic beta-AntagonistsHemodynamicsRenal functionBlood PressureKidney Function TestsPlaceboEssential hypertensionDrug Administration ScheduleRenal CirculationInternal medicineHeart ratemedicineAdrenergic antagonistBisoprololHumansPharmacology (medical)Antihypertensive Agentsbusiness.industryessential hypertensionGeneral MedicineMiddle Agedmedicine.diseaseBlood pressureBisoprololHypertensionCardiologyFemalebusinessmedicine.drugAdvances in Therapy
researchProduct

Changes in estimating echocardiography pulmonary capillary wedge pressure after hypersaline plus furosemide versus furosemide alone in decompensated …

2011

BACKGROUND: The aim of the study was to verify the effects of hypertonic saline solution (HSS) plus a high furosemide dose and light restriction of sodium intake compared with a high-dose infusion of furosemide alone on pulmonary capillary wedge pressure (PCWP), as determined by Doppler echocardiography and tissue Doppler imaging in patients suffering from decompensated heart failure. METHODS AND RESULTS: Consecutive patients in New York Heart Association functional class IV, unresponsive to oral high doses of furosemide up to 250-500 mg/d and/or combinations of diuretics, with ejection fraction <40%, serum creatinine <2 mg/dL, blood urea nitrogen ≤60 mg/dL, reduced urinary volume (<500 mL/…

MaleSettore MED/09 - Medicina Internamedicine.medical_treatmentHemodynamicsDoppler echocardiographyDouble-Blind MethodFurosemidemedicinePlethysmographHumansPlethysmography ImpedancePulmonary Wedge PressurePulmonary wedge pressureDiureticsAgedAged 80 and overHeart FailureSaline Solution HypertonicEjection fractionmedicine.diagnostic_testDiuretics Saline Solution Hypertonic Furosemide PCWPbusiness.industryFurosemidemedicine.diseaseEchocardiographyHeart failureAnesthesiaFemaleDiureticCardiology and Cardiovascular Medicinebusinessmedicine.drug
researchProduct